Optimer (OPTR) Says FDA Committee Reviewing NDA for Fidaxomicin in Clostridium
Tweet Send to a Friend
Optimer (Nasdaq: OPTR) says FDA committee ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
